On Wednesday, Shares of Baxter International Inc. (NYSE:BAX), gained 2.29% to $38.86.
Baxter International, declared the determination of the Total Consideration for all series of notes listed in the table below in connection with Baxter’s formerly declared cash tender offers for specified series of its outstanding debt. The Total Consideration for the 3.650% Notes due August 2042 was fixed at the commencement of the Tender Offers.
The terms and conditions of the Tender Offers are described in Baxter’s Offer to Purchase and the related Letter of Transmittal.
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
Shares of Gilead Sciences Inc. (NASDAQ:GILD), declined -0.91% to $116.01, during its last trading session.
Gilead Sciences, declared that it has presented a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen that combines Gilead’s emtricitabine 200 mg and tenofovir alafenamide (TAF) 25 mg with rilpivirine 25 mg (R/F/TAF) from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older. The data presented in the NDA support the use of R/F/TAF among patients who are HIV treatment-naïve or who are virologically suppressed and want to replace their current antiretroviral treatment regimen.
A Priority Review voucher attained from Knight Therapeutics in November 2014 was presented to the FDA together with the R/F/TAF NDA. Under the Prescription Drug User Fee Act (PDUFA), the anticipated target action date for the R/F/TAF NDA is six months after the FDA’s acceptance of the filing.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The company’s products comprise Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease.
Finally, Goldcorp Inc. (NYSE:GG), ended its last trade with -1.98% loss, and closed at $15.88, hitting its lowest level.
Tahoe Resources Inc., declared the closing of the formerly declared secondary offering of Tahoe shares beneficially held by Goldcorp Inc.. A total of 58,051,692 Tahoe common shares beneficially held by Goldcorp were sold at an offering price of CAD$17.20 per share (the Offering). The Offering was accomplished through a syndicate of underwriters led by GMP Securities L.P. and BMO Nesbitt Burns Inc. acting as joint book-runners and counting CIBC World Markets Inc., HSBC Securities (Canada) Inc., RBC Dominion Securities Inc., Scotia Capital Inc., TD Securities Inc., Citigroup Global Markets Canada Inc., Credit Suisse Securities (Canada), Inc., Goldman Sachs Canada Inc., Laurentian Bank Securities Inc., Merrill Lynch Canada Inc., Morgan Stanley Canada Ltd., Beacon Securities Limited, Canaccord Genuity Corp., Cormark Securities Inc., Dundee Securities Ltd., Macquarie Capital Markets Canada Ltd., Paradigm Capital Inc. and Raymond James Ltd.
As a result of the Offering, Goldcorp no longer owns any common shares of Tahoe. Tahoe did not receive any proceeds from the Offering.
Goldcorp Inc. engages in the acquisition, exploration, development, and operation of precious metal properties in Canada, the United States, Mexico, and Central and South America. The company primarily explores for gold, silver, copper, lead, and zinc deposits.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
